OPEN TO ENROLLMENT

Clinical Trial of Everolimus in Children and Adolescents with PTEN Mutations

WHO
• Individuals ages 6-21 with a PTEN Mutation who meet a series of safety inclusion criteria

WHAT
• 6-month randomized controlled trial with everolimus (RAD001)
• Evaluate safety of everolimus and its potential to improve neurocognition

HOW
• Developmental Testing
• Safety Blood Tests
• Eye-tracking
• Electrophysiological Measures

For more information please contact Robin Libove at rlibove@stanford.edu.

The Developmental Synaptopathies Consortium (U54NS092090) is a part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), NCATS. This consortium is funded through a collaboration between the NCATS, the NINDS and the NIMH.